CELECOR THERAPEUTICS
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.
CELECOR THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2017-01-01
Address:
Del Mar, California, United States
Country:
United States
Website Url:
http://www.celecor.com
Status:
Active
Contact:
+1 858 777 9750
Total Funding:
3.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apache Amazon Google Apps For Business Amazon Virginia Region
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Board_member
Current Employees Featured
Barry Coller Co-Founder @ CeleCor Therapeutics
Co-Founder
Robert Hillman President, CEO, and Co-Founder @ CeleCor Therapeutics
President, CEO, and Co-Founder
Andreas Ritzi Co-Founder @ CeleCor Therapeutics
Co-Founder
2017-01-01
Founder
Official Site Inspections
http://www.celecor.com
- Host name: ec2-35-91-131-11.us-west-2.compute.amazonaws.com
- IP address: 35.91.131.11
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "CeleCor Therapeutics"
About Us - CeleCor Therapeutics
Robert S. Hillman, PhD, is a biomedical engineer and successful serial entrepreneur/inventor. He studied at Stanford University, MIT, and the Swiss Federal Institute of Technology (ETH-Z).See details»
CeleCor Therapeutics - Crunchbase Company Profile
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous …See details»
CeleCor Therapeutics - Org Chart, Teams, Culture
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous …See details»
CeleCor Therapeutics Company Profile 2024: Valuation, Funding ...
CeleCor Therapeutics is headquartered in Del Mar, CA. What is the size of CeleCor Therapeutics? CeleCor Therapeutics has 6 total employees. What industry is CeleCor …See details»
CeleCor Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore CeleCor Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, Technology Platform:Small molecule drug, Drug:Zalunfiban. ... The statistics for …See details»
Celecor Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Celecor Therapeutics, Inc. of Del Mar, CA. Get the latest business insights from Dun & Bradstreet.See details»
CeleCor Therapeutics - LinkedIn
CeleCor Therapeutics | 916 followers on LinkedIn. Let's start treatment for patients with a heart attack BEFORE they reach the hospital because Time is Muscle. | We’re a biotechnology …See details»
CeleCor Therapeutics - Leadership Team - The Org
The Leadership Team at CeleCor Therapeutics is responsible for setting the strategic direction of the company, overseeing the development and commercialization of their novel small …See details»
CeleCor Therapeutics - VentureRadar
CeleCor Therapeutics was founded to develop zalanfiban (RUC-4) , a novel small molecule platelet inhibitor of the platelet GPIIb/IIIa (aIIbß3) receptor, designed for single dose …See details»
CeleCor Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Mar 8, 2022: Venture Round - …See details»
CeleCor Therapeutics - Craft
CeleCor Therapeutics is a company that provides a solution supporting the treatment of serious heart attacks. It develops RUC-4, a small molecule platelet inhibitor of the platelet GPIIb/IIIa …See details»
CeleCor Therapeutics - Contacts, Employees, Board Members, …
Organization. CeleCor Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... About. CeleCor Therapeutics has 3 current employee profiles, …See details»
CeleCor Therapeutics - Company Profile - Tracxn
Oct 21, 2024 CeleCor Therapeutics - Developer of POC subcutaneous injectable for treating myocardial infarction. Raised a total funding of $46.5M over 2 rounds from 1 investor. …See details»
CeleCor Therapeutics - Overview, News & Similar companies
Who is CeleCor Therapeutics. CeleCor Therapeutics, Inc. is a biotechnology company focused on developing a first-point-of-contact therapy to improve the treatment of serious he art attacks, …See details»
About Zalunfiban - CeleCor Therapeutics
50% of heart-attack deaths occur before a patient reaches the hospital. 1 Dudas et al, Trends in Out-of-Hospital Deaths Due to Coronary Heart Disease in Sweden (1991 to 2006). Circulation. …See details»
CeleCor Therapeutics Announces Positive First-in-Human Data of …
Sep 25, 2019 CeleCor Therapeutics, Inc. is a biotechnology company focused on developing a first-point-of-contact therapy to improve the treatment of serious heart attacks, specifically ST …See details»
Prof. Jur Ten Berg Presents Clinical Trial Results of Zalunfiban (RUC …
Click here for the press release of the study sponsor CeleCor Therapeutics, Inc. CeleCor Therapeutics, Inc. is a biotechnology company focused on developing a first-point-of-contact …See details»
Clinical Trials - CeleCor Therapeutics
CeleCor designs a randomized, placebo-controlled clinical trial to study zalunfiban or placebo, subcutaneously injected in STEMI patients treated in ambulances at the first point of contact. …See details»
Prehospital treatment with zalunfiban (RUC-4) in patients with ST ...
Apr 1, 2023 He serves as a scientific advisory to CeleCor. J.M. ten Berg reports grants from the Netherlands Organization for Health Research and Development, a Dutch government …See details»